Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김선일 | - |
dc.date.accessioned | 2018-03-15T05:19:50Z | - |
dc.date.available | 2018-03-15T05:19:50Z | - |
dc.date.issued | 2012-11 | - |
dc.identifier.citation | Investigative Ophthalmology and Visual Science, November 2012, 53(12), P.7693-7700 | en_US |
dc.identifier.issn | 0146-0404 | - |
dc.identifier.issn | 1552-5783 | - |
dc.identifier.uri | http://iovs.arvojournals.org/article.aspx?articleid=2127410 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/47117 | - |
dc.description.abstract | PURPOSE. We evaluated the potential of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a noninvasive biomarker of choroidal neovascularization (CNV) and its utility as a tool for monitoring therapeutic response in laser-induced rat CNV models.METHODS. CNV was induced in the right eyes of 14 rats using a laser. Rats (n = 7) were treated daily for 14 days with a candidate drug (KR-31831, 50 mg/kg of body weight) having antiangiogenic effects, whereas control rats (n - 7) were treated with the vehicle alone (10% cremophor, 10% absolute ethyl alcohol, and 80% saline). DCE-MRI examinations were performed on the day before surgery (D - 1), and 3, 7, and 14 days after surgery (D + 3, D + 7, and D + 14), from which pharmacokinetic parameters (K-trans, v(e), v(p)) were calculated. Angiography was performed to visualize CNV using FITC-labeled high molecular weight dextran after MRI on D + 14. The paired Wilcoxon test and Mann-Whitney U test were performed for statistical analysis.RESULTS. The K-trans and v(e) values of the CNV-induced right eyes were significantly higher than those of the intact eyes in control rats at D+14 (P < 0.05). In the CNV-induced eyes, the relative K-trans and v(e) values of the KR-31831-treated group were significantly lower than those of the nontreated group at D + 14 (P < 0.05). The angiography showed that decreased CNV was observed in rats treated with KR-31831.CONCLUSIONS. Quantitative DCE-MRI produces noninvasive biomarker of CNV, thus allowing monitoring of therapeutic response of antiangiogenic drugs in neovascular age-related macular degeneration (AMD). (Invest Ophthalmol Vis Sci. 2012;53:7693-7700) DOI:10.1167/iovs.12-9805 | en_US |
dc.description.sponsorship | Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2011-0031520 and 2010-0023606). | en_US |
dc.language.iso | en | en_US |
dc.publisher | ASSOC RESEARCH VISION OPHTHALMOLOGY INC | en_US |
dc.subject | BLOOD-RETINAL BARRIER | en_US |
dc.subject | ANTIANGIOGENIC AGENT KR-31831 | en_US |
dc.subject | MACULAR DEGENERATION | en_US |
dc.subject | PARAMETERS | en_US |
dc.subject | ANGIOGENESIS | en_US |
dc.subject | PERMEABILITY | en_US |
dc.subject | BEVACIZUMAB | en_US |
dc.subject | MACULOPATHY | en_US |
dc.subject | TUMORS | en_US |
dc.subject | DTPA | en_US |
dc.title | Dynamic Contrast-Enhanced MRI for Assessing Therapeutic Response of Choroidal Neovascularization in a Rat Model | en_US |
dc.type | Article | en_US |
dc.relation.no | 12 | - |
dc.relation.volume | 53 | - |
dc.identifier.doi | 10.1167/iovs.12-9805 | - |
dc.relation.page | 7693-7700 | - |
dc.relation.journal | INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | - |
dc.contributor.googleauthor | Kim, Jae-Hun | - |
dc.contributor.googleauthor | Im, Geun Ho | - |
dc.contributor.googleauthor | Yoon, Jaemoon | - |
dc.contributor.googleauthor | Yang, Jehoon | - |
dc.contributor.googleauthor | Chung, Julius Juhyun | - |
dc.contributor.googleauthor | Cha, Ji Hoon | - |
dc.contributor.googleauthor | Ham, Don-il | - |
dc.contributor.googleauthor | Lee, Jung Hee | - |
dc.contributor.googleauthor | Kim, Sun I | - |
dc.relation.code | 2012204427 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DIVISION OF ELECTRICAL AND BIOMEDICAL ENGINEERING | - |
dc.identifier.pid | sunkim | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.